| Patents for A61P 19 - Drugs for skeletal disorders (81,981) |
|---|
| 01/02/2002 | EP1165185A2 Human tumor necrosis factor receptor-like 2 |
| 01/02/2002 | EP1165184A2 Estrogen receptor-beta antagonism and bone diseases |
| 01/02/2002 | EP1165143A2 Method for expressing proteins |
| 01/02/2002 | EP1165139A2 Pharmaceutical compositions comprising in combination a bisphosphonate and a matrix metalloproteinasese inhibitor |
| 01/02/2002 | EP1165137A1 Sphingomyelin containing preparation for the enhancement of tumor therapy |
| 01/02/2002 | EP1165115A1 Modulation of vascular permeability by mean of tie2 receptor activators |
| 01/02/2002 | EP1165114A1 Use of a lectin or conjugates for modulation of c-fibre activity |
| 01/02/2002 | EP1165101A2 Induction of antigen-specific unresponsiveness by glioblastoma culture supernatants (gcs) |
| 01/02/2002 | EP1165085A1 Phthalazine derivatives for treating inflammatory diseases |
| 01/02/2002 | EP1165081A1 Tolperison-containing, pharmaceutical preparation for oral administration |
| 01/02/2002 | EP1165072A2 Valdecoxib compositions |
| 01/02/2002 | EP1165064A2 Novel inhibitors of formation of advanced glycation endproducts (age's) |
| 01/02/2002 | EP1165061A2 Compound preparation made of vitamin d metabolites or vitamin d analogues and an oestrogenic component for treating osteoporosis |
| 01/02/2002 | EP1164863A1 Pet food for maintenance of joint health and alleviation of arthritic symptoms in companion animals |
| 01/02/2002 | EP1135151A4 Peptoid and nonpeptoid containing alpha-keto oxadiazoles as serine protease inhibitors |
| 01/02/2002 | EP1005372B1 Anti-cd40l immunotoxins for the treatment of diseases |
| 01/02/2002 | EP0600079B1 Oral 1alpha-hydroxyprevitamin d |
| 01/02/2002 | CN1329620A Analogues of GLP-1 |
| 01/02/2002 | CN1329610A Chromenone and chromanone derivatives as integrin inhibitors |
| 01/02/2002 | CN1329607A Substituted benzopyran analogs for treatment of inflammation |
| 01/02/2002 | CN1329499A Pharmaceutical preparation containing cyclopeptide and chemotherapeutic agent or angiogenesis inhibitor |
| 01/02/2002 | CN1329495A Use of ibandronate for promoting osseointegration of endoprostheses |
| 01/02/2002 | CN1328841A Medicine for preventing and curing asteoporosis and promoting union and its production method |
| 01/02/2002 | CN1328831A Bone-strengthening powder and its preparation method |
| 01/02/2002 | CN1328820A Application of calcium L-threonate for curing fracture |
| 01/02/2002 | CN1077103C Chiral methyl phenyl oxazolidinones |
| 01/01/2002 | US6335457 Complex containing biologically assimilable orthosilicic acid, which is under solid form, stable and concentrated, and a process for preparation of said complex |
| 01/01/2002 | US6335433 nrdD |
| 01/01/2002 | US6335349 Agents that reduce levels of tumor necrosis factor; anticarcinogenic and antiinflammatory agents; treatment of autoimmune diseases |
| 01/01/2002 | US6335338 Calcilytic compounds |
| 01/01/2002 | US6335333 Matrix metalloproteinase inhibitors |
| 01/01/2002 | US6335332 Barbituric acid derivatives with antimetastatic and antitumor activity |
| 01/01/2002 | US6335329 Carboxylic acid substituted heterocycles, derivatives thereof and methods of use |
| 01/01/2002 | US6335195 Method for promoting hematopoietic and mesenchymal cell proliferation and differentiation |
| 01/01/2002 | US6335038 Propionyl l-carnitine and the isoflavone genistein for treatment of osteoporosis and menopause syndrome |
| 12/29/2001 | CA2342059A1 Angiogenesis inhibitor |
| 12/27/2001 | WO2001098497A1 Secreted epithelial colon stromal-1 polypeptides, nucleic acids encoding the same and uses thereof |
| 12/27/2001 | WO2001098493A1 Insulin-like growth factor-binding protein |
| 12/27/2001 | WO2001098491A2 Osteolevin gene polymorphisms |
| 12/27/2001 | WO2001098490A1 A g-protein coupled receptor |
| 12/27/2001 | WO2001098362A2 Chemically-modified antimicrobial peptides, compositions and methods of production and use |
| 12/27/2001 | WO2001098353A2 Secreted proteins |
| 12/27/2001 | WO2001098347A1 Canine liver cell growth factor |
| 12/27/2001 | WO2001098344A2 Angiogenesis-modulating compositions and uses |
| 12/27/2001 | WO2001098332A2 Secreted redox proteins |
| 12/27/2001 | WO2001098330A2 A RECOMBINANT CELL LINE EXPRESSING GPCRx11 AS A FUNCTIONAL RECEPTOR VALIDATED BY ANGIOPEPTIN AND USEFUL FOR SCREENING OF AGONISTS AND ANTAGONISTS |
| 12/27/2001 | WO2001098323A2 G-protein coupled receptors |
| 12/27/2001 | WO2001098295A1 Novel 1,3-dihydro-2h-indol-one derivatives, method for preparing same and pharmaceutical compositions containing them |
| 12/27/2001 | WO2001098291A2 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat vcam-1 mediated disorders |
| 12/27/2001 | WO2001098289A1 Novel non-psychotropic cannabinoids |
| 12/27/2001 | WO2001098278A1 Methods and compositions utilizing quinazolinones |
| 12/27/2001 | WO2001098273A1 Novel compounds |
| 12/27/2001 | WO2001098270A2 N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| 12/27/2001 | WO2001098256A1 Thyroid receptor ligands, pharmaceutical compositions comprising them and their use in the treatment of disorders influenced by thyroid hormones |
| 12/27/2001 | WO2001097860A2 Pharmaceuticals for the imaging of angiogenic disorders for use in combination therapy |
| 12/27/2001 | WO2001097850A2 Combinations and compositions which interfere with vegf/vegf and angiopoietin/tie receptor function and their use (ii) |
| 12/27/2001 | WO2001097837A1 Solubilised protein vaccines |
| 12/27/2001 | WO2001097795A2 Systems and methods for treating a mucosal surface |
| 12/27/2001 | WO2001097788A2 Method of administering bisphosphonates |
| 12/27/2001 | WO2001085719A9 Ortho-substituted anthranilic acid amides and their use as medicaments |
| 12/27/2001 | WO2001068811A3 Method for in vitro production of three-dimensional vital cartilage or bone tissue and use thereof as transplant material |
| 12/27/2001 | WO2001060356B1 Method for improving bone modeling and chondrocyte functioning in growing canines |
| 12/27/2001 | WO2001057042A3 4-pyridyl-and 2,4-pyrimidinyl-substituted pyrrole derivatives and their use in pharmacy |
| 12/27/2001 | WO2001049711A3 Nucleic acids encoding (poly)peptides having chips activity |
| 12/27/2001 | WO2001047564A3 Labelled ascorbic acid derivatives |
| 12/27/2001 | WO2001046256A3 Vesicle trafficking proteins |
| 12/27/2001 | WO2001039795A3 Attenuation of fibroblast proliferation |
| 12/27/2001 | WO2001035975A3 Treatment of subnormal bone mineral density |
| 12/27/2001 | WO2001032646A3 Sulfonamide derivatives |
| 12/27/2001 | WO2001023390A3 Azepinoindole derivatives, the production and use thereof |
| 12/27/2001 | WO2001021159A3 Pharmaceutical composition of nateglinide and another antidiabetcagent |
| 12/27/2001 | WO2000055109A9 Lipoxin compounds and their use |
| 12/27/2001 | US20010056184 Pipecolinic acid derivatives, method of manufacturing the same and therapeutic agents containing these compounds |
| 12/27/2001 | US20010056183 Sulfonamides and derivatives thereof that modulate the activity of endothelin |
| 12/27/2001 | US20010056113 Methods for the inhibition of angiogenesis with 6-amino EM-12 |
| 12/27/2001 | US20010056110 Systemic use of 5-HT3 receptor antagonists against rheumatic inflammatory processes |
| 12/27/2001 | US20010056107 Cyano and carboxy derivatives of substituted styrenes are inhibitors of tumor necrosis factor alpha , nuclear factor kappa B, and phosphodiesterase and can be used to treat cachexia, endotoxic shock, inflammatory conditions etc. |
| 12/27/2001 | US20010056105 Useful as cosmetic for hair and body hygiene, and for treatment of dermatological complaints, with an inflammatory and/or immunoallergic component of rheumatic or respiratory type, cardivascular and opthalmogical disorders |
| 12/27/2001 | US20010056100 Carboxylic acid or tetrazole derivatives containing carbamate groups are useful for treating the conditions associated with the urinary tract, pain, inflammation, respiratory states, edema formation of hypotensive vascular diseases |
| 12/27/2001 | US20010056099 Method of reducing morbidity and the risk of mortality |
| 12/27/2001 | US20010056092 Diaminocyclobutene-3,4-dione derivatives, their preparation and use |
| 12/27/2001 | US20010056060 Treatment of osteoporsis with EP2/EP4 receptor selective agonists |
| 12/27/2001 | CA2414228A1 Secreted epithelial colon stromal-1 polypeptides, nucleic acids encoding the same and uses thereof |
| 12/27/2001 | CA2414010A1 Secreted redox proteins |
| 12/27/2001 | CA2413878A1 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat vcam-1 mediated disorders |
| 12/27/2001 | CA2413754A1 Canine hepatocyte growth factor |
| 12/27/2001 | CA2413454A1 A g-protein coupled receptor |
| 12/27/2001 | CA2413435A1 A recombinant cell line expressing gpcrx11 as a functional receptor validated by angiopeptin and useful for screening of agonists and antagonists |
| 12/27/2001 | CA2413421A1 N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| 12/27/2001 | CA2413328A1 Pharmaceuticals for the imaging of angiogenic disorders for use in combination therapy |
| 12/27/2001 | CA2412484A1 G-protein coupled receptors |
| 12/27/2001 | CA2412215A1 Angiogenesis-modulating compositions and uses |
| 12/27/2001 | CA2412110A1 Osteolevin gene polymorphisms |
| 12/27/2001 | CA2412011A1 Chemically-modified antimicrobial peptides, compositions and methods of production and use |
| 12/27/2001 | CA2411585A1 Novel non-psychotropic cannabinoids |
| 12/27/2001 | CA2411236A1 Combinations and compositions which interfere with vegf/vegf and angiopoietin/tie receptor function and their use (ii) |
| 12/27/2001 | CA2410208A1 Systems and methods for treating a mucosal surface |
| 12/27/2001 | CA2409778A1 Secreted proteins |
| 12/26/2001 | CN1328573A Cross-linked hyaluronic acids and medical uses thereof |
| 12/26/2001 | CN1328545A Hydrazine derivatives |